This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Oxyntomodulin, Mechanisms of Action in Relation to Appetite, Food Intake, Gastric Emptying and Energy Expenditure.

This study has been completed.
Information provided by (Responsible Party):
Jonatan I Bagger, University Hospital, Gentofte, Copenhagen Identifier:
First received: November 1, 2010
Last updated: December 9, 2013
Last verified: December 2013

Tiny molecules (hormones) are released from the bowels and other organs to the bloodstream in response to meals in order to orchestrate the metabolism. Oxyntomodulin, GLP-1 and glucagon are all known to regulate parameters such as appetite, food intake and induce weight loss.

Therefore we want to investigate mechanistic relations between the three hormones.

Condition Intervention
Incretin Action Obesity Other: GLP-1 infusion Other: Glucagon infusion Other: Oxyntomodulin infusion Other: GLP-1 and glucagon infusion Other: Placebo

Study Type: Observational

Further study details as provided by Jonatan I Bagger, University Hospital, Gentofte, Copenhagen:

Primary Outcome Measures:
  • Gastric emptying [ Time Frame: 4 h ]
    Assessed by the acetaminophen - method

  • Satiety [ Time Frame: 4 h ]
    Assessed by VAS

  • Hunger [ Time Frame: 4 h ]
    Assessed by an ad'libitum meal

  • basal energy expenditure [ Time Frame: 2 x 30min ]
    Assessed by indirect calorimetry

Secondary Outcome Measures:
  • GLP-1 [ Time Frame: 4 h ]
  • Oxyntomodulin [ Time Frame: 4 h ]
  • Glucagon [ Time Frame: 4 h ]
  • GIP [ Time Frame: 4 h ]

Biospecimen Retention:   Samples With DNA
blood samples

Enrollment: 15
Study Start Date: October 2010
Study Completion Date: January 2012
Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Healthy young males Other: GLP-1 infusion
1 pmol/kg/min
Other: Glucagon infusion
Other: Oxyntomodulin infusion
3 pmol/kg/min
Other: GLP-1 and glucagon infusion
1 pmol/kg/min 3 ng/kg/min
Other: Placebo
NaCl 9 g/L infusion


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Healthy young males

Inclusion Criteria:

  • Normal fasting plasma glucose
  • Normal glucose tolerance
  • Normal haemoglobin levels
  • Informed content

Exclusion Criteria:

  • Diabetes
  • Pre diabetes (impaired glucose tolerance or impaired fasting glucose)
  • 1st degree relatives with diabetes
  • Obesity (BMI > 30)
  • Inflammatory bowels disease
  • Bowels surgery
  • Nephropathy
  • Liver disease
  • Medication which cannot be on hold for 24h
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01232244

Gentofte University Hospital
Hellerup, Denmark, 2900
Sponsors and Collaborators
University Hospital, Gentofte, Copenhagen
Principal Investigator: Jonatan I Bagger, MD Gentofte University Hospital, University of Copenhagen
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Jonatan I Bagger, MD, University Hospital, Gentofte, Copenhagen Identifier: NCT01232244     History of Changes
Other Study ID Numbers: OXMDissek
Study First Received: November 1, 2010
Last Updated: December 9, 2013

Keywords provided by Jonatan I Bagger, University Hospital, Gentofte, Copenhagen:
Incretin hormones
Energy expenditure

Additional relevant MeSH terms:
Glucagon-Like Peptide 1
Gastrointestinal Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Incretins processed this record on September 19, 2017